Atara Bio's PINTA 745 Improves Insulin Sensitivity and Alters Fat Metabolism in Mice Fed With a High Fat Diet

Atara Biotherapeutics, Inc. ATRA, a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced the publication of preclinical data that provide insight into the pharmacology of its clinical stage anti-myostatin peptibody, PINTA 745. In the International Journal of Obesity, investigators from Baylor College of Medicine utilized a high fat diet (HFD)-fed mouse model of obesity and type II diabetes to evaluate the effects of myostatin inhibition using PINTA 745. The paper is available at the following web location: http://www.nature.com/ijo/journal/vaop/naam/index.html#05102015 "The data published today further clarify the molecular mechanisms of PINTA 745's pharmacology. The ongoing phase 2 clinical trial with PINTA 745 includes collection of preliminary data on insulin sensitivity, inflammation, and body composition in patients with End-Stage Renal Disease," said Christopher Haqq, MD, PhD, Chief Medical Officer of Atara Bio. "We intend to further explore the role of myostatin inhibition in glucose and fat metabolism."